AscellaHealth has been given an industry award for a financial solution designed to meet the affordability challenges of expensive treatments for rare and complex diseases
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh